BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seixas S, Marques PI. Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum. Appl Clin Genet 2021;14:173-94. [PMID: 33790624 DOI: 10.2147/TACG.S257511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Elkhalifa D, Rayan M, Negmeldin AT, Elhissi A, Khalil A. Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases. Biomed Pharmacother 2022;145:112385. [PMID: 34915673 DOI: 10.1016/j.biopha.2021.112385] [Reference Citation Analysis]
2 Park SS, Rodriguez Ortega R, Agudelo CW, Perez Perez J, Perez Gandara B, Garcia-Arcos I, McCarthy C, Geraghty P. Therapeutic Potential of Alpha-1 Antitrypsin in Type 1 and Type 2 Diabetes Mellitus. Medicina (Kaunas) 2021;57:397. [PMID: 33923873 DOI: 10.3390/medicina57040397] [Reference Citation Analysis]
3 Schouten IGM, Mumford RA, Moes DJAR, Hiemstra PS, Stolk J. The Course of AαVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients. Int J Mol Sci 2021;22:8031. [PMID: 34360796 DOI: 10.3390/ijms22158031] [Reference Citation Analysis]
4 Presotto MA, Veith M, Trinkmann F, Schlamp K, Polke M, Eberhardt R, Herth F, Trudzinski FC. Clinical characterization of a novel alpha1-antitrypsin null variant: PiQ0Heidelberg. Respir Med Case Rep 2022;35:101570. [PMID: 35028284 DOI: 10.1016/j.rmcr.2021.101570] [Reference Citation Analysis]
5 Martinez-González C, Blanco I, Diego I, Bueno P, Miravitlles M. Estimated Prevalence and Number of PiMZ Genotypes of Alpha-1 Antitrypsin in Seventy-Four Countries Worldwide. Int J Chron Obstruct Pulmon Dis 2021;16:2617-30. [PMID: 34556982 DOI: 10.2147/COPD.S327803] [Reference Citation Analysis]